Evidence map›Paper›PMID 40391706›Full record

ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

The Immune Microenvironment: New Therapeutic Implications in Organ Fibrosis.

Xiangqi Chen, Chuan Wu, Fei Tang, Jingyue Zhou, Li Mo, Yanping Li, Jinhan He

Abstract readReview
In one paragraph

Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Integrating mechanical cues inFrontiers in immunology · 2026
    Review
  8. The Immune Microenvironment: New Therapeutic Implications in Organ Fibrosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiangqi ChenDepartment of Pharmacy, Institute of Metabolic Diseases and Pharmacotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Chuan WuState Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Fei TangState Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Jingyue ZhouState Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Li MoCenter of Gerontology and Geriatrics, West China Hospital, Sichuan University, Chengdu, 610041, China.
Yanping LiDepartment of Pharmacy, Institute of Metabolic Diseases and Pharmacotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Jinhan HeDepartment of Pharmacy, Institute of Metabolic Diseases and Pharmacotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.ORCID https://orcid.org/0000-0001-6487-4696

Funding

China Postdoctoral Science Foundation 2024M762203Innovation Group Project from Science & Technology Department of Sichuan Province 23NSFTD0067National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University Z2024YY003National Natural Science Foundation of China 82025007National Natural Science Foundation of China 82170874National Natural Science Foundation of China 82270923National Natural Science Foundation of China U24A20676Youth Foundation from Sichuan Province 2023NSFSC1543
6 · The paper itself

Abstract

Fibrosis, characterized by abnormal deposition of structural proteins, is a major cause of tissue dysfunction in chronic diseases. The disease burden associated with progressive fibrosis is substantial, and currently approved drugs are unable to effectively reverse it. Immune cells are increasingly recognized as crucial regulators in the pathological process of fibrosis by releasing effector molecules, such as cytokines, chemokines, extracellular vesicles, metabolites, proteases, or intercellular contact. Therefore, targeting the immune microenvironment can be a potential strategy for fibrosis reduction and reversion. This review summarizes the recent advances in the understanding of the immune microenvironment in fibrosis including phenotypic and functional transformations of immune cells and the interaction of immune cells with other cells. The novel opportunities for the discovery and development of drugs for immune microenvironment remodeling and their associated challenges are also discussed.

Indexed as

Cellular MicroenvironmentFibrosisAnimalsHumansimmune microenvironmentorgan fibrosistherapeutic targets

Identifiers

PMID40391706
PMCPMC12376546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.